Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (100/62.5/2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ERJ Open Res
Autors principals: Fenwick, Elisabeth, Martin, Alan, Schroeder, Melanie, Mealing, Stuart J., Solanke, Oyinkansola, Risebrough, Nancy, Ismaila, Afisi S.
Format: Artigo
Idioma:Inglês
Publicat: European Respiratory Society 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983252/
https://ncbi.nlm.nih.gov/pubmed/33778055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00480-2020
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars